6833.HKライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 11:40):

Stats
本日の出来高	16 000.00
平均出来高	94 465.00
時価総額	483.83M
EPS	HKD0 ( 2023-08-30 )
Last Dividend	HKD0.00980 ( 2023-05-31 )
Next Dividend	HKD0 ( N/A )
P/E	23.80
ATR14	HKD0 (0.00%)

Sinco Pharmaceuticals 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Sinco Pharmaceuticals 財務諸表

Annual	2022
収益:	HKD2.27B
総利益:	HKD305.87M (13.47 %)
EPS:	HKD0.0342

FY	2022
収益:	HKD2.27B
総利益:	HKD305.87M (13.47 %)
EPS:	HKD0.0342

FY	2021
収益:	HKD2.02B
総利益:	HKD364.95M (18.03 %)
EPS:	HKD0.0800

FY	2020
収益:	HKD2.05B
総利益:	HKD273.83M (13.36 %)
EPS:	HKD0.0700

Financial Reports:

No articles found.

Sinco Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.00980 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Sinco Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.62 - good (96.24%) | Divividend Growth Potential Score: 5.48 - Stable (9.62%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.00330	2016-09-09
Last Dividend	HKD0.00980	2023-05-31
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	HKD0.0131	--
Avg. Dividend % Per Year	0.00%	--
Score	2.49	--
Div. Sustainability Score	9.62
Div.Growth Potential Score	5.48
Div. Directional Score	7.55	--

Next Divdend (Est)
(2029-12-31)

HKD0.0174 Estimate 2.59 %

Dividend Stability

0.21 Very Poor

Dividend Score

2.49

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6806.HK	Ex Dividend Knight	2023-06-26	Annually	0.00%
1908.HK	Ex Dividend Junior	2023-06-01	Sporadic	0.00%
0941.HK	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
0064.HK	Ex Dividend Knight	2023-08-29	Semi-Annually	0.00%
2888.HK	Ex Dividend Junior	2023-08-10	Annually	0.00%
1508.HK	Ex Dividend Junior	2023-06-29	Annually	0.00%
0558.HK	Ex Dividend Junior	2023-09-12	Annually	0.00%
8095.HK	Ex Dividend Junior	2023-10-17	Sporadic	0.00%
2009.HK	No Dividend Player	2023-05-18	Annually	0.00%
1084.HK	Ex Dividend Junior	2023-06-06	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0122	1.500	9.76	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0165	1.200	9.45	10.00	[0 - 0.3]
returnOnEquityTTM	0.0449	1.500	-0.612	-0.919	[0.1 - 1]
payoutRatioTTM	0.668	-1.000	3.32	-3.32	[0 - 1]
currentRatioTTM	1.183	0.800	9.08	7.27	[1 - 3]
quickRatioTTM	0.818	0.800	9.90	7.92	[0.8 - 2.5]
cashRatioTTM	0.517	1.500	8.24	10.00	[0.2 - 2]
debtRatioTTM	0.125	-1.500	7.92	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.203	2.00	9.93	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.180	2.00	9.91	10.00	[0 - 20]
debtEquityRatioTTM	0.339	-1.500	8.64	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.119	1.000	-1.345	-1.345	[0.2 - 0.8]
operatingProfitMarginTTM	0.0343	1.000	-1.314	-1.314	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.01	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	1.359	0.800	4.27	3.42	[0.5 - 2]
Total Score				9.62

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	16.08	1.000	8.48	0	[1 - 100]
returnOnEquityTTM	0.0449	2.50	-0.394	-0.919	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.180	2.00	9.94	10.00	[0 - 30]
dividendYielPercentageTTM	4.56	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.203	2.00	9.93	10.00	[0 - 30]
payoutRatioTTM	0.668	1.500	3.32	-3.32	[0 - 1]
pegRatioTTM	1.554	1.500	2.97	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.185	1.000	7.87	0	[0.1 - 0.5]
Total Score				5.48

Sinco Pharmaceuticals

Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers Octapharma, a human albumin solution for use in premature infants; Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections; and Medocef that is used for the treatment of bacterial infections, such as the infections of the lower respiratory tract comprising pneumonia, urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and sepsis. It also provides Esafosfina, which is used for treating hypophosphatemia and chronic diseases, including alcohol intoxication, malnutrition, and hypophosphatemic respiratory failure; Taurolite, a third generation oral cholic acid drug that is used for the treatment of gallstone diseases; and Tamifil injection for the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis. In addition, the company engages in the sale of pharmaceutical products; and provides warehouse facilities for pharmaceutical products; and offers international trade services, as well as provides consultation services for medical and biological technology. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited is a subsidiary of Risun Investments Limited.